By Colin Kellaher

 

Ionis Pharmaceuticals is teaming up with longtime partner Roche Holdings on a pair of early stage programs for RNA-targeting investigational medicines for the treatment of the brain disorders Alzheimer's disease and Huntington's disease.

Ionis on Wednesday said it will have responsibility to advance the two programs through pre-clinical studies, while Roche will have sole responsibility for clinical development and commercialization worldwide.

Ionis said it will receive a $60 million upfront payment from Roche, adding that it is eligible for development, regulatory and commercial milestone payments, along with royalties.

Carlsbad, Calif.-based Ionis and Swiss drug giant Roche have been working together since 2013 and have candidates in clinical studies targeting Huntington's, IgA nephropathy and geographic atrophy.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

September 27, 2023 07:44 ET (11:44 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Gráfica de Acción Histórica
De Abr 2024 a May 2024 Haga Click aquí para más Gráficas Roche (QX).
Roche (QX) (USOTC:RHHBY)
Gráfica de Acción Histórica
De May 2023 a May 2024 Haga Click aquí para más Gráficas Roche (QX).